RT-A1

RT-A1 is a novel, unimolecular peptide designed to act as a dual activator of the particulate guanylate cyclase receptors GC-A and GC-B. By activating GC-A, it mimics the effects of atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP), promoting arteriodilation, natriuresis, and antihypertrophic effects. Simultaneously, its activation of GC-B mimics C-type natriuretic peptide (CNP), mediating antifibrotic, lusitropic, and anti-inflammatory actions. Developed through rational drug design by researchers at Vanderbilt University and the Mayo Clinic, RT-A1 has demonstrated the ability to attenuate adverse myocardial remodeling, reduce hypertrophy, and downregulate inflammatory pathways in preclinical models of heart failure with preserved systolic function.